Drugs News and Research

RSS

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

At the 17th Conference on Retroviruses and Opportunistic Infections (CROI), ViiV Healthcare presented new data across its broad range of investigational and current medicines for the treatment of HIV/AIDS. Highlighted data at the conference included an oral presentation on the investigational integrase inhibitor, S/GSK1349572, as well as data presentations on SELZENTRY® (maraviroc) and EPZICOM® (abacavir/lamivudine).

24 Feb 2010

Recreational drugs can trigger memory lapse

Have you ever forgotten to post an important letter or let an appointment slip your mind? A new study from UK researchers suggests that for those who regularly use ecstasy or other recreational drugs, this kind of memory lapse is more common.

24 Feb 2010

Clout of drug industry seen in MD residency programs and in health reform

News outlets report on the pharmaceutical industry's involvement in doctor training and its role in shaping the health care overhauls pending in Congress.

24 Feb 2010

Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy

Ocera Therapeutics, Inc. announced today that the ASTUTE Study (AST-120 Used to Treat Hepatic Encephalopathy) has completed enrollment for its Phase 2B study ahead of schedule, with data expected mid 2010.

24 Feb 2010

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).

23 Feb 2010

NASDAQ halts trading of Salix Pharmaceuticals stock, FDA Committee to discuss XIFAXAN NDA

Salix Pharmaceuticals, Ltd. today announced that NASDAQ has halted trading of the Company’s common stock this morning. The Gastrointestinal Drugs Advisory Committee of the FDA is meeting today to discuss the efficacy and safety of the New Drug Application (NDA) for XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy.

23 Feb 2010

Medco Health Solutions announces record 16.7% increase in total net revenues for 2009

Medco Health Solutions, Inc. today reported record fourth-quarter 2009 GAAP diluted earnings per share of $0.70, up 29.6 percent compared to $0.54 in fourth-quarter 2008. Excluding the amortization of intangible assets that existed when Medco became a publicly traded company in 2003, fourth-quarter 2009 diluted earnings per share increased 28.8 percent to a record $0.76. Medco also reported record full-year 2009 GAAP diluted earnings per share of $2.61, up 22.5 percent -- exceeding the high-end of the company's guidance.

23 Feb 2010

Gross sales of Acorda Therapeutics' ZANAFLEX CAPSULES and tablets increase 9.1% to $58.3M in 2009

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2009.

23 Feb 2010

Behavioral Neuroscience: Adolescents more susceptible to internal and environmental factors

While the otherworldly behavior of teenagers is well documented, University of Pittsburgh researchers have taken a significant step toward finally unraveling the actual brain activity that can drive adolescents to engage in impulsive, self-indulgent, or self-destructive behavior.

23 Feb 2010

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Cayston® (aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. Cayston’s safety and efficacy have not been established in pediatric patients below the age of 7, patients with forced expiratory volume in one second of less than 25 percent or greater than 75 percent predicted, or patients colonized with Burkholderia cepacia.

23 Feb 2010

Obecure granted patent covering betahistine with olanzapine for mitigating antipsychotic drug associated weight gain

Obecure Ltd., a subsidiary of Bio-Light Israeli Life Science Investments Ltd., has received notice of allowance from the US Patent Office for its two key patent applications covering methods of use and compositions covering the use of betahistine with olanzapine for the mitigation of the serious weight gain associated as a side effect of the antipsychotic drug.

23 Feb 2010

Combining PARP inhibitors with existing cancer drugs promising

Ovarian and breast cancer treatments being developed that mix a protein inhibitor and traditional anticancer drugs are showing signs of success, according to a new review for Faculty of 1000 Biology Reports.

23 Feb 2010

Committee calls for strategies to curb hypertension

Public health officials and health care providers need to step up their efforts to reduce Americans' increasing rates of high blood pressure and better treat those with the condition, which triggers more than one-third of heart attacks and almost half of heart failures in the United States each year, says a new report from the Institute of Medicine.

23 Feb 2010

News outlets examine use of ART, microbicide development presented at conference

News outlets continue to report on the science discussed at the Conference on Retroviruses and Opportunistic Infections (CROI), which ended Friday in San Francisco.

23 Feb 2010

Black women are more prone to peripartum cardiomyopathy around childbirth time

A study examining the incidence of peripartum cardiomyopathy in women who gave birth at a Medical College of Georgia's teaching hospital between July 2003 and July 2008, showed that while 55 percent of the women were white, 93 percent of those who developed cardiomyopathy were black, said Dr. Mindy B. Gentry, an MCG cardiologist.

23 Feb 2010

Eon Labs to pay $3.5M for resolving False Claims Act allegations concerning Nitroglycerin SR capsules

Eon Labs Inc. has agreed to pay the United States $3.5 million to resolve False Claims Act allegations relating to the company's drug Nitroglycerin Sustained Release (SR) capsules, the Justice Department announced today. Eon Labs is a subsidiary of Sando Inc., which is in turn a subsidiary of Novartis AG.

23 Feb 2010

Nursing workforce issues: An expanded role for nurse practitioners, Calif. doctors sue for supervision of nurse anesthetists

News outlets report on nursing workforce issues, including a push for an expanded role for nurse practitioners, supervision of nurse anesthetists and a trend toward delayed retirement.

23 Feb 2010

CINJ researchers test malaria drug for colorectal cancer treatment

While new cases of colorectal cancer continue to decline in the United States, it remains the third leading cause of cancer death in the nation, according to the American Cancer Society. That is why researchers at The Cancer Institute of New Jersey are looking to add a drug known for fighting malaria to traditional chemotherapy for colorectal cancer to see if treatment can be made more effective for patients.

23 Feb 2010

Cancer Institute awards MCRA designation to Cooper University Hospital

Enhancing its collective strength in the area of oncology research in the state, The Cancer Institute of New Jersey has announced that Cooper University Hospital will be the fourth affiliate hospital within its Network to receive the prestigious Major Clinical Research Affiliate designation.

23 Feb 2010

Global rules barring TB patients from flying are too stringent, study says

A "controversial" study, released on Sunday, "suggests international rules that bar potentially infectious tuberculosis patients from flying are too stringent and airline passengers are really at little risk from catching TB from a fellow traveler," the Associated Press/Washington Post reports. The paper is being published in the March edition of Lancet Infectious Diseases (Stobbe, 2/21).

23 Feb 2010

Drugs News and Research

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

Recreational drugs can trigger memory lapse

Clout of drug industry seen in MD residency programs and in health reform

Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

NASDAQ halts trading of Salix Pharmaceuticals stock, FDA Committee to discuss XIFAXAN NDA

Medco Health Solutions announces record 16.7% increase in total net revenues for 2009

Gross sales of Acorda Therapeutics' ZANAFLEX CAPSULES and tablets increase 9.1% to $58.3M in 2009

Behavioral Neuroscience: Adolescents more susceptible to internal and environmental factors

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

Obecure granted patent covering betahistine with olanzapine for mitigating antipsychotic drug associated weight gain

Combining PARP inhibitors with existing cancer drugs promising

Committee calls for strategies to curb hypertension

News outlets examine use of ART, microbicide development presented at conference

Black women are more prone to peripartum cardiomyopathy around childbirth time

Eon Labs to pay $3.5M for resolving False Claims Act allegations concerning Nitroglycerin SR capsules

Nursing workforce issues: An expanded role for nurse practitioners, Calif. doctors sue for supervision of nurse anesthetists

CINJ researchers test malaria drug for colorectal cancer treatment

Cancer Institute awards MCRA designation to Cooper University Hospital

Global rules barring TB patients from flying are too stringent, study says

Drug Discovery - Second Edition eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News